Tesamorelin
Synthetic growth hormone releasing hormone variant evaluated for abdominal adipose reduction.
Open Tesamorelin in the 3D analyzerAnalytical specification
| Empirical formula | C221H366N72O67S |
|---|---|
| Molecular weight | 5135.9 g/mol |
| Isoelectric point (pI) | 9.10 |
| Assay purity (HPLC) | 99.38% |
| Retention time | 6.50 min |
| Peak area / height | 13900 / 1110 |
| Reference batch | TE-2026-S77 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Hexenoyl-Y-A-D-A-I-F-T-N-S-Y-R-K-V-L-G-Q-L-S-A-R-K-L-L-Q-D-I-M-S-R-Q-Q-G-E-S-N-Q-E-R-G-A-R-A-R-L-NH2 |
Research characteristics
Lipodystrophy Target
Targets deep visceral fatty clusters
GHRH Agonist
Preserves physiological feedback loop
Cognitive Marker
Explored in age-related recall models
Anabolic Support
Improves recovery and protein synthesis
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.